The International Cholesterol Management Practice Study (ICLPS) South Africa investigated achievement of European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline low-density lipoprotein cholesterol (LDL-C) targets in real-world clinical practice. Demographic data, clinical characteristics, cardiovascular risk factors, lipidmodifying medications, lipid values and investigator's assessment of cardiovascular risk were recorded for 396 patients on stable lipid-modifying therapy. Most (98.7%) patients received statins; 25.1% of statin-treated patients were receiving highintensity statins. Overall, 41.4% of patients achieved their LDL-C target; among 354 (89.4%) patients in whom cardiovascular disease risk, based on ESC Systematic Coronary Risk Estimation (SCORE) was calculated, achievement rate was 14.3% for moderate-risk (n = 7), 59.3% for high-risk (n = 123) and 32.3% for very high-risk patients (n = 223). Half of Asian (54.7%) and black African (53.2%) patients were at LDL-C target compared with 29.8% of European/Caucasian and 27.3% of 'other' patients. Improved guideline adherence and greater use of combination therapy may increase LDL-C goal achievement.
Despite improvements in its identification, prevention and treatment, cardiovascular disease (CVD) remains the world's leading cause of morbidity and mortality. 1 Furthermore, Africa in general, and South Africa specifically, are experiencing an increasing burden of CVD. 2, 3 Dyslipidaemia is a major risk factor for atherosclerotic CVD and the primary goal of dyslipidaemia treatment is to reduce levels of low-density lipoprotein cholesterol (LDL-C) to targets recommended by clinical practice guidelines. 4, 5 Statins are the preferred choice of lipid-modifying therapy (LMT) because of their proven efficacy and safety, and their relatively low cost. 6, 7 Addition of another LMT, such as ezetimibe or bile-acid sequestrant, to statin therapy is an option for patients who are not at target LDL-C on statins alone; however, these non-statin therapies have limited efficacy in lowering LDL-C. 5 More effective LMTs, such as the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab 8 and evolocumab, 9 are not yet approved for use in South Africa.
Large studies conducted predominantly in Western Europe and North America have shown that LDL-C levels remain elevated in many patients at high cardiovascular risk, despite the wide availability of statins. [10] [11] [12] Similar results were reported for the CEntralised Pan-South African survey on tHE Undertreatment of hypercholesterolaemia (CEPHEUS SA) 13 and the DYSlipidaemia International Study (DYSIS), 14 which found that less than half of patients treated for dyslipidaemia achieved their LDL-C goals. Several factors may contribute to the under-treatment of dyslipidaemia in South Africa, including limited availability and lack of affordability of statins, use of low doses, frequent use of low-potency statins, statin intolerance, non-adherence to therapy and inadequate response to treatment.
In the public health sector, treatment is limited by restrictive formularies that allow for only modest statin doses to be prescribed for most patients. In the private sector, restrictions imposed by medical funders make it difficult for many patients to access high-intensity statins. Many funders require titration from low-dose to high-dose statins for reimbursement; however, dose titration is infrequent in practice. For example, in CEPHEUS SA, of 2 996 patients with dyslipidaemia treated with LMT for three months or longer, 63.5% had remained on their initial starting treatment and dose at the time of assessment, and only 8.7% had had their dose increased. 13 Medical funders frequently AFRICA impose co-payments on certain statins or ezetimibe, thus, in effect making them unavailable to many patients if they cannot afford the co-payments. The International Cholesterol Management Practice Study (ICLPS) was a multinational observational study that investigated the achievement of European Society of Cardiology (ESC)/ European Atherosclerosis Society (EAS) guideline LDL-C targets 5 and their determinants in real-world clinical practice in countries outside of Western Europe. 15 In this article, we report the findings from ICLPS participants in South Africa and assess whether the management of patients with dyslipidaemia has improved since reporting of the CEPHEUS SA 13 and DYSIS 14 studies.
Methods
This cross-sectional, observational study was conducted in 19 centres in South Africa. The study was conducted according to the principles laid out by the 18th World Medical Assembly in the Declaration of Helsinki (Helsinki, 1964) and all subsequent amendments, the guidelines for Good Epidemiology Practice, and according to local regulations. Ethics approval was obtained from university ethics committees for academic sites (Universities of Cape Town and the Witwatersrand) and from a central ethics committee (Pharma Ethics) for all other sites. All patients provided written informed consent. Patients (≥ 18 years of age) who had been receiving a stable dose and type of LMT for at least three months before enrolment, and who had their LDL-C value measured on stable LMT in the previous 12 months, were eligible to participate. Patients participating in a clinical trial or who had received a PCSK9 inhibitor in the previous six months were excluded. The first patient was enrolled in August 2015 and the last patient in February 2016.
A national expert advised on the relative contribution of each medical speciality to the management of patients with dyslipidaemia in South Africa. This information, together with a feasibility study, was used to identify suitable physician investigators and to ensure the results would adequately reflect the real-world management of patients with dyslipidaemia. Bias in the selection of study sites was limited by independently selecting participating centres and physicians in a randomised manner from pre-established lists, aiming to ensure a balanced representation of each speciality. To limit bias in patient selection, investigators were instructed to approach all eligible patients consecutively and recruit all patients who provided consent (minimum of five patients recruited per site) during a predefined two-week interval at each site.
Physicians completed a questionnaire collecting demographic data, medical speciality, years of practice, type of practice and its location, main workplace, mean number of patients consulted per day, choice of and adherence to practice guidelines for lipid disorders [that is, ESC/EAS, 5 American College of Cardiology/ American Heart Association (ACC/AHA), 7 other international guidelines or local/national guidelines], and the definition of statin intolerance used in their practice (that is, intolerance to one, two or three or more statins).
For each patient, the investigator completed a case-report form during a single visit. Data collected included demographic data, physical examination findings, cardiovascular risk factors, medical history, type of hypercholesterolaemia (primary or familial), LDL-C and other lipid values (calculated or measured directly at the site's local laboratory, on current treatment and untreated if available), current LMTs, socio-economic profile and the investigator's assessment of the patient's cardiovascular risk level.
Data quality control was performed at a randomly selected sample (≥ 10%) of sites by trained personnel.
Statistical analysis
Baseline characteristics are presented as descriptive statistics with mean ± standard deviation (SD) or median (interquartile range) for continuous variables, and as counts (percentages) for categorical data. The primary outcome was the proportion of patients taking LMT who had failed to achieve their appropriate LDL-C targets at enrolment, as defined by the 2011 ESC/EAS guidelines: < 1.8 mmol/l (∼70 mg/dl) or 50% LDL-C reduction (for those patients for whom baseline untreated LDL-C was available) when target levels could not be reached for very highrisk patients, < 2.5 mmol/l (∼100 mg/dl) for high risk, and < 3.0 mmol/l (∼115 mg/dl) for moderate risk. 5 The Systematic Coronary Risk Estimation (SCORE) chart 5 for high-risk countries was used to retrospectively risk stratify patients in whom the relevant data were available. The high-risk chart was used owing to the increasing rate of CVD in non-European countries.
The SCORE algorithm 16 assesses 10-year risk of fatal CVD, based on gender, age, smoking status, systolic blood pressure and total serum cholesterol. In the ICLPS SA, pre-treatment total serum cholesterol values were used; consequently, not all patients could be classified according to risk level. Low-risk patients were those with a SCORE value < 1% and moderate risk was a SCORE value ≥ 1% and < 5%. Patients with a SCORE value ≥ 5% or with systolic blood pressure ≥ 180 mmHg and diastolic blood pressure ≥ 110 mmHg, or with familial hypercholesterolemia as per the Dutch Lipid Clinic Network algorithm (definite or probable), or with diabetes without target-organ damage were classified in the high-risk group. The very high-risk group included patients with a 10-year risk of fatal CVD ≥ 10% or with at least one of the following conditions: documented coronary artery disease (CAD), cerebrovascular disease or peripheral artery disease, type 2 diabetes with target-organ damage, and history of chronic kidney disease (glomerular filtration rate < 60 ml/min/1.73 m²). Patients without a serious pathology classifying them as very high or high cardiovascular risk, and in whom the SCORE could not be calculated owing to missing data (most commonly baseline LDL-C) were categorised as non-assessable.
Results
A total of 19 physicians participated in the study as investigators (age 50.6 ± 8.4 years; 63.2% men). (A full list of participating physician investigators is provided at the end.*) More than half (57.9%) were general practitioners or family physicians, and the rest included specialists in endocrinology (10.5%), cardiology, lipidology, internal medicine (each 5.3%) or another field (15.8%). Participating physicians had been in practice for a mean ± SD of 22.9 ± 8.3 years.
Most physicians (57.9%) were in practices that treated mostly private patients, 21.1% were in practices that treated mostly public patients, and 21.1% were in mixed practices that treated both public and private patients. Overall, 78.9% of practices were in urban areas. All physicians reported adhering to dyslipidaemia guidelines: 57.9% to ESC/EAS, 31.6% to ACC/AHA and 5.3% to other international guidelines. In addition, 42.1% stated that they adhered to the local South African guidelines, which are closely aligned with the ESC/EAS guidelines. Statin intolerance was defined as intolerance to one, two or three statins by 15.8, 47.4 and 36.8% of physicians, respectively.
Of 427 patients assessed, 31 were ineligible for enrolment ( Fig. 1) . Therefore, the study population comprised 396 patients (mean ± SD age, 60.0 ± 10.2 years; 56.3% men) ( Table  1) . Patient demographic and clinical characteristics, lipid values and LMTs are shown according to cardiovascular risk level in Tables 1 and 2 .
Overall, 36.4% were Caucasian/European, 24.7% were Asian (including South Asian) and 24.2% were black African. Most (n = 367, 92.7%) patients were from urban/suburban areas, and 81.1% (n = 317) had completed secondary education or higher. A total of 279 (70.5%) patients had private medical insurance. Most patients (81.8%) had healthcare cover (public or private) that included drug reimbursement (private medical insurance) or drug supply (public sector).
Most (87.1%) were overweight or obese [defined as a body mass index (BMI) of 25 to < 30 kg/m 2 and ≥ 30 kg/ m 2 , respectively], 57.3% were physically inactive, 53.9% had the metabolic syndrome (Adult Treatment Panel III), 13.4% were current smokers and 22.0% reported regular alcohol consumption. Diabetes mellitus was present in 65.2% and hypertension in 81.3% of patients. A total of 135 (34.1%) patients had documented CAD: previous acute coronary syndrome (88/135, 65.2%), percutaneous coronary intervention (75/135, 55.6%) or coronary artery bypass graft surgery (57/135, 42.2%).
Median time since dyslipidaemia diagnosis was 6.0 (interquartile range 3.0-12.0) years. The LDL-C value at the time of first diagnosis was available in 130 (32.8%) patients; mean untreated LDL-C was 3.9 ± 1.4 mmol/l (151.7 ± 52.7 mg/dl) and the LDL-C range was 0.7-9.0 mmol/l (27.0-347.5 mg/dl). At first diagnosis, 63.8% (83/130) of patients had an LDL-C value > 3.4 mmol/l (130 mg/dl) and 18.5% (24/130) had LDL-C > 4.9 mmol/l (190 mg/dl). Definite or probable familial hypercholesterolaemia was reported in 6.2% of patients.
Of the 354 (89.4%) patients in whom SCORE cardiovascular risk could be calculated, 63.0% were at very high risk, 34.7% at high risk, 2.0% at moderate risk and 0.3% (one patient) was at low risk. Physician-estimated risk correlated poorly with calculated risk (Fig. 2) ; physicians underestimated risk in 54.7% of patients at very high calculated risk and 38.2% of those at high risk. Tables 3 and 4 show patient demographic and clinical characteristics, lipid values and LMTs by patient ethnicity. A smaller proportion of black African patients were male (35.4%) compared with other ethnic groups (53.4-72.2%). In the black African patient group, the incidences of obesity and hypertension were 63.5 and 89.6%, respectively. Corresponding figures in the other ethnic groups ranged from 32.7 to 54.2% for obesity and 71.5 to 87.9% for hypertension. Rates of documented CAD were 10.4% in black Africans compared with 28.6 to 50.0% in other ethnic groups.
At study enrolment, 98.7% of patients were receiving statin therapy; 90.7% were receiving statin monotherapy, 3.3% were receiving statin plus a fibrate, and 2.6% were receiving a statin plus a cholesterol-absorption inhibitor (Table 1) . One-quarter of patients treated with statins were receiving high-intensity statin therapy (that is, atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg) and 17.7% were on the highest-dose regimen available in South Africa at the time of the study.
Mean LDL-C value at enrolment was 2.6 ± 1.0 mmol/l (98.7 ± 39.6 mg/dl) ( Table 2) . Overall, 41.4% of patients were at or below their LDL-C target at enrolment ( Figs 3A and 4) . Among patients for whom SCORE cardiovascular risk could be assessed, achievement rates were 14.3, 59.3 and 32.3% for those at moderate, high and very high risk, respectively (Fig.  3A) . Around half of Asian (54.7%) and black African (53.2%) patients achieved their LDL-C target compared with 29.8% of European/Caucasian patients and 27.3% of patients of 'other' ethnicity (Fig. 3B) ; achievement rates ranged from 65.0% in patients seen by physicians with several specialities to 6.3% in patients under the care of a cardiologist (Fig. 3C) .
Discussion
This observational study in patients on stable LMT indicated that achievement of LDL-C goals in South Africa is inadequate, ).
despite the availability of local and international dyslipidaemia management guidelines with well-publicised LDL-C targets. Fewer than half of patients (41.4%) were at or below their LDL-C target, and target achievement rates were lower (32.3%) for those patients at very high cardiovascular risk and moderate risk (14.3%). These results are consistent with the overall findings of the ICLPS study, which demonstrated that lipid management remains suboptimal in countries outside of Western Europe. 15 Similar rates of LDL-C goal achievement (∼50%) were reported for previous studies conducted in South Africa, 13, 14 demonstrating a lack of improvement in dyslipidaemia management over recent years. Factors that may contribute to low LDL-C goal achievement rates include prescription of inadequate statin doses, use of moderate-or low-potency statins, failure to titrate statin dosages, failure to use combination therapy, poor adherence and limited effectiveness of current LMTs, particularly for achieving the lower LDL-C goals recommended for patients at very high cardiovascular risk. There was poor agreement between physician-estimated cardiovascular risk and risk assessed using SCORE; in general, physicians underestimated risk. As a patient's LDL-C goal depends on assessment of their cardiovascular risk, this underestimation may result in a lack of intensification of LMT, leaving many patients undertreated. There may be a need for better dissemination of local lipid-management guidelines to improve physicians' understanding of risk assessment and to promote adherence to guideline recommendations.
Funder barriers and affordability may also limit the use of appropriate doses and intensity of statin therapy, as well as the use of combination therapy with ezetimibe. IMPROVE-IT demonstrated that the addition of ezetimibe to statin therapy resulted in an incremental lowering of LDL-C and improved cardiovascular outcomes in patients with acute coronary syndrome (ACS). 17 The proportion of patients on a statin plus ezetimibe in the current study was low, and greater use of this combination may improve LDL-C goal attainment.
Cost and lack of access are major reasons for the low use of ezetimibe. It is envisaged that generic ezetimibe will enter the market in South Africa soon. Its lower cost, together with the findings of IMPROVE-IT, 16 may increase access and uptake of ezetimibe, at least for patients at very high risk of atherosclerotic CVD. In addition, the introduction of novel LMT combinations, not yet available in South Africa, may further improve dyslipidaemia management and reduce the risk of cardiovascular events.
Recent studies have demonstrated the efficacy of the PCSK9 inhibitors in high-risk patients treated with statins. 8, 9 In FOURIER, evolocumab reduced LDL-C levels by 59% and cardiovascular events by 15% compared with placebo in patients treated with statins who had atherosclerotic CVD and LDL-C ≥ 70 mg/dl (1.8 mmol/l). 9 ODYSSEY OUTCOMES examined the effect of alirocumab in patients with a recent ACS and elevated cholesterol level despite intensive or maximum-tolerated statin therapy. 8 Rates of major adverse cardiovascular events and all-cause mortality were reduced by 15% with alirocumab versus placebo.
The findings of the present study revealed socio-economic differences between ethnic groups, which may reflect a legacy of the previous political system that limited opportunities for black South Africans. For example, 57.9% of black African patients had completed secondary or university education compared with 86.7% of Asian and 99.4% of Caucasian/European patients. In addition, rates of private health insurance cover were lower in black African patients (50.0%) than in Asian (77.6%) and Caucasian/Europeans (93.1%).
Rates of obesity (63.5%) and hypertension (62.5%) were high in black African patients. It should be noted that obesity was defined as BMI ≥ 30 kg/m 2 for all patients; however, a lower cut-off point may be more appropriate in Asian patients. 18 Consequently, the true rate of obesity in Asian patients may be higher than that observed in this group (32.7%).
Diabetes mellitus, a major risk factor for CVD, was also highly prevalent in both black African (78.1%) and Asian (87.8%) patients compared with Caucasians/Europeans (42.4%). These differences between ethnic groups contrast with those from the South African National Health and Nutrition Examination Survey (SANHANES-1), which examined the prevalence of Statin + fibrate ± other LMT, n (%) 13 ( non-communicable diseases and their risk factors in the general population in South Africa in 2012. 19 SANHANES-1 noted a lower rate of self-reported diabetes in black African participants than with Asian (13.6%) and white (6.9%) participants, and similar or lower levels of obesity and hypertension compared with other ethnic groups. However, SANHANES-1 was a general population study, whereas this study examined a highly selected population receiving LMT.
Changes in the political system have now made access to cities possible for black South Africans, and many have migrated from rural to urban areas. This has likely resulted in a greater adoption of a sedentary lifestyle and increased consumption of refined foods, which may have contributed to a rise in cardiovascular risk factors relative to other ethnic groups. Despite the lower level of education and private health cover, and high rates of cardiovascular risk factors in black African patients, LDL-C target attainment rate was 53.2% in this group compared with 54.7% in Asians and 29.8% in Caucasian/Europeans. Better LDL-C target achievement in black African patients may partially be due to the high prevalence of diabetes mellitus in the black African patients included in our sample, as LDL hypercholesterolaemia is characteristically not very severe in patients with diabetes. In addition, familial hypercholesterolaemia is relatively common in Caucasian/European individuals, and to a lesser extent in Asian South Africans, due to founder effects. Achieving LDL-C goals in patients with familial hypercholesterolaemia is more difficult, owing to very high baseline LDL-C values.
A very low proportion of patients attained their LDL-C goal when treated by a cardiologist or lipidologist. This may be due to the higher proportion of patients with severe dyslipidaemia, such as familial hypercholesterolaemia, managed by these specialities. Patients with familial hypercholesterolaemia are unlikely to reach LDL-C goal with LMTs that are currently available in South Africa, and novel agents, such as PCSK9 inhibitors, would be required to manage these patients.
Limitations
This study was subject to limitations that may influence its findings. The study population is not fully representative of all patients treated with LMT in South Africa. The participants AFRICA comprised mainly educated patients residing in urban areas with a high rate of private healthcare insurance, in contrast with the general population, in which most patients are treated in the public health sector. In addition, the study only included patients on stable LMT; therefore, patients with untreated dyslipidaemia are not represented. We were therefore unable to estimate what proportion of patients with an indication for LMT was receiving treatment.
Owing to the observational nature of the study, and in accordance with the study design, LMTs and doses varied according to site/physician preference, and patient adherence to LMTs was not assessed. SCORE was used to assess cardiovascular risk; however, its validity in non-European populations has not been established. Only one patient was classified as at low risk; therefore, the findings are not representative of this group. In addition, missing data may have limited some analyses, including LDL-C values at first diagnosis, and the diagnosis of familial hypercholesterolaemia based upon genetic/family history data.
Conclusion
Achievement of LDL-C goals is suboptimal in South Africa, particularly in patients at moderate and very high cardiovascular risk. Physicians' assessment of cardiovascular risk was poor, and the use of high-dose statin or combination therapy was low, highlighting a gap between guideline recommendations and clinical practice. Sociodemographic differences between ethnic groups may also influence the management of dyslipidaemia. Improving adherence to guidelines, increasing the use of combination therapy, and the introduction of novel LMTs are important strategies for improving LDL-C goal achievement. Statin + fibrate ± other LMT, n (%) 13 ( 
